All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Average Weight Loss On Zepbound: By Month

Explore the average weight loss on Zepbound by month. See dose-by-dose expectations, monthly milestones, and strategies for staying on track throughout...

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

Average Weight Loss On Zepbound: By Month custom 2026 header image for GLP-1 Weight Loss
Custom header image for Average Weight Loss On Zepbound: By Month, GLP-1 Weight Loss, and better treatment decision-making.
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Search and AI answer brief

Practical answer: Average Weight Loss On Zepbound: By Month

Explore the average weight loss on Zepbound by month. See dose-by-dose expectations, monthly milestones, and strategies for staying on track throughout...

Short answer

Explore the average weight loss on Zepbound by month. See dose-by-dose expectations, monthly milestones, and strategies for staying on track throughout...

Search intent

This page answers a specific GLP-1 Weight Loss question rather than a generic overview.

What to verify

semaglutide, tirzepatide, retatrutide, cash price and coverage terms

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

Explore the average weight loss on Zepbound by month. See dose-by-dose expectations, monthly milestones, and strategies for staying on track throughout treatment.

Zepbound (tirzepatide) produces rapid and sustained weight loss, with patients losing an average of 5 to 6 pounds per month in the first half-year and reaching total losses of 15% to 21% of body weight by month 18. As the newest FDA-approved weight management medication, Zepbound has set a new benchmark for monthly weight loss results.

Because Zepbound and Mounjaro contain compounded formulations of the active ingredient (tirzepatide), the monthly weight loss data from both the SURMOUNT and SURPASS trial programs applies. But since Zepbound is specifically approved for weight management, we will focus here on the SURMOUNT data, which studied tirzepatide in the obesity population. what is Zepbound

Zepbound Monthly Weight Loss Timeline

Zepbound's dose titration starts at 2.5 mg and increases in 2.5 mg increments every 4 weeks. Patients can reach a maintenance dose of 5 mg, 10 mg, or 15 mg based on their individual response and provider guidance.

Zepbound Monthly Weight Loss (15 mg Track, SURMOUNT-1[1] Data, Avg Starting Weight 231 lbs)
Month Dose Monthly Weight Loss Cumulative Loss (%) Cumulative Pounds Lost
1 2.5 mg 4 to 6 lbs 2.0% 4 to 6 lbs
2 5 mg 5 to 7 lbs 4.5% 9 to 13 lbs
3 7.5 mg 5 to 7 lbs 7.5% 15 to 20 lbs
4 10 mg 4 to 6 lbs 10.0% 21 to 27 lbs
5 12.5 mg 4 to 5 lbs 12.5% 27 to 32 lbs
6 15 mg 3 to 5 lbs 14.5% 32 to 38 lbs
9 15 mg 2 to 3 lbs 18.0% 39 to 44 lbs
12 15 mg 1 to 2 lbs 19.5% 43 to 47 lbs
18 15 mg 0.5 to 1 lb 20.9% ~48 lbs

How Results Vary by Maintenance Dose

Not every patient needs or tolerates the 15 mg dose. Here is how the 12-month results compare across dose levels.

Zepbound 12-Month Results by Maintenance Dose
Maintenance Dose Avg 12-Month Weight Loss Approximate Pounds Lost (from 231 lbs)
5 mg ~14% ~32 lbs
10 mg ~18% ~42 lbs
15 mg ~20% ~46 lbs

Even the lowest maintenance dose of 5 mg produces results that match or exceed what most other GLP-1 medications deliver at their highest doses. Zepbound dosing options

Month-by-Month Patient Experience

Month 1: Foundation Setting

At 2.5 mg, your body begins adjusting to tirzepatide. The most notable change is appetite reduction. Most patients describe feeling less interested in food overall, not just eating less but genuinely wanting less. Weight loss of 4 to 6 pounds is typical and encouraging. For a complete cost breakdown, see our compare tirzepatide pharmacies.

GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Illustration for Average Weight Loss On Zepbound: By Month

Side effects during the first month are usually manageable. Nausea affects roughly 15% to 25% of patients and tends to improve within the first 10 days. Eating smaller, more frequent meals and avoiding fatty or greasy foods helps minimize discomfort. Zepbound first month guide

Month 2: Momentum Building

At 5 mg, the appetite-suppressing effects become stronger. Many patients notice that they naturally stop eating sooner during meals and that cravings for high-calorie foods decrease. The monthly loss rate often peaks during months 2 and 3, when the dose is increasing but the body hasn't yet adjusted to the new metabolic rate.

Cumulative weight loss reaches approximately 4% to 5% of starting weight. For most patients, this is enough to start feeling physically lighter and more energetic.

Month 3: Visible Transformation Begins

By month 3, the cumulative weight loss (15 to 20 pounds for many patients) becomes visible. Faces slim, waistlines reduce, and clothing becomes noticeably looser. This is often the month when friends, family, and coworkers begin commenting on changes.

From a health perspective, fasting blood sugar, blood pressure, and inflammatory markers frequently show measurable improvement by this point. Many patients report sleeping better and experiencing less joint discomfort. early health improvements on Zepbound

Months 4 to 6: Peak Transformation Phase

Dose titration continues through these months for patients heading to 10 mg, 12.5 mg, or 15 mg. Weight loss remains strong at 3 to 6 pounds per month. Cumulative losses of 14% to 15% of starting weight are common by month 6.

This phase is significant both physically and psychologically. Patients frequently describe feeling like a different person. Confidence increases, physical limitations decrease, and the relationship with food fundamentally shifts from one of struggle to one of control.

Months 7 to 12: Steady Continuation

Monthly weight loss rates moderate to 1 to 3 pounds during this phase. The deceleration is normal and reflects the body's metabolic adjustment to a lower weight. Total weight loss continues to accumulate, reaching 18% to 20% of starting weight by month 12 on the 15 mg dose.

This period is important for establishing the habits that will sustain your results long term. The appetite-suppressing effects of Zepbound remain strong, giving you a continued advantage in making healthy food choices and controlling portions.

Beyond 12 Months

The SURMOUNT-1 trial continued through 18 months, and weight loss was still occurring, though slowly, at the end of the study. The SURMOUNT-4 trial[2] additionally showed that patients who continued treatment after 36 weeks maintained and extended their weight loss, while those who stopped regained. This reinforces the value of sustained treatment.

Evaluating Your Monthly Progress

Our providers use these general benchmarks to evaluate whether a patient's Zepbound treatment is progressing well.

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →
  • By month 1: Any weight loss plus noticeable appetite changes
  • By month 3: At least 5% of starting body weight lost
  • By month 6: At least 10% of starting body weight lost
  • By month 12: At least 15% of starting body weight lost (on 10 mg or 15 mg)

Patients who are below these thresholds may benefit from dose adjustments, dietary improvement, or investigation of potential contributing factors. Our team works with each patient individually to troubleshoot and improve.

Tips for Consistent Monthly Progress

Weigh yourself weekly, not daily. Daily weight fluctuates based on water, sodium, and digestion. A weekly weigh-in at the same time under the same conditions gives you a cleaner picture of your monthly trend. weight tracking best practices

Photograph your progress monthly. Visual changes are often more motivating than scale changes, and photos give you a permanent record of your transformation. Take front, side, and back photos in similar clothing each month.

Increase protein as you increase dose. As your appetite decreases further with higher doses, making sure each meal starts with protein helps preserve muscle mass. Aim for at least 0.6 to 0.8 grams of protein per pound of your target body weight daily.

Add resistance training by month 3. Starting strength training early in your Zepbound process helps ensure that the weight you lose is predominantly fat. This results in better body composition and helps avoid the "deflated" look that can accompany rapid weight loss without exercise. strength training on GLP-1 medication

Frequently Asked Questions

Is it normal to lose 8 pounds in one month on Zepbound?

Losing 8 pounds in a single month is within the normal range, especially during months 2 through 4 when dose increases are actively occurring. Some patients lose even more during peak months. As long as you aren't experiencing severe side effects, this rate is healthy and sustainable with Zepbound.

What if I only lost 2 pounds this month on Zepbound?

A 2-pound month isn't cause for alarm, especially after the first 6 months of treatment when the rate naturally slows. But if you're in the early months (2 through 6) and consistently losing less than 2 pounds per month, discuss this with your provider to determine if a dose adjustment is warranted.

Does Zepbound work faster than Wegovy?

In the early months, Zepbound and Wegovy produce similar monthly weight loss rates. But Zepbound pulls ahead in the middle and later months, resulting in significantly greater total weight loss by month 12 and beyond. The monthly difference becomes more pronounced as both medications reach their full maintenance doses. Zepbound vs Wegovy monthly comparison

When do most people reach their lowest weight on Zepbound?

Based on the SURMOUNT-1 data, weight loss continues through at least 18 months without reaching a clear plateau. Most patients reach their lowest weight either at the end of their trial period or continue losing modestly beyond 18 months. This suggests that long-term treatment produces ongoing, if gradual, results.

Medical References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
  2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]

Track Your Monthly Results with FormBlends

FormBlends provides physician-supervised Zepbound and tirzepatide treatment with structured monthly progress evaluations. Our clinical team helps you understand whether your monthly results are on track, when dose adjustments might help, and how to improve your lifestyle for the best possible outcomes. get started with FormBlends

Start your consultation today and begin tracking your Zepbound weight loss with expert clinical support.

Talk to a licensed provider

Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.

Start the assessment →

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
Mounjaro evidence source
Official source
Ozempic evidence source
Official source
Retatrutide evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Zepbound evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Average Weight Loss On Zepbound: By Month, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Randomized trialTirzepatide evidence2025

Tirzepatide for Obesity Treatment and Diabetes Prevention

Supports newer discussion of obesity treatment and diabetes-prevention outcomes.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Direct answer

Average Weight Loss On Zepbound: By Month research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

FormBlends Editorial Context

Reviewed May 14, 2026

Explore the average weight loss on Zepbound by month. See dose-by-dose expectations, monthly milestones, and strategies for staying on track throughout treatment. "Average Weight Loss On Zepbound: By Month" earns its keep when it helps a reader move from a broad question to a cleaner next step. This is a GLP-1 treatment guide where medication choice, dosing, side effects, monitoring, and insurance rules can change the decision, and the reader usually needs help with patient education and clinical context. Pay extra attention to tirzepatide, dosing and related tags such as GLP-1, weight management, weight loss. Because this article has 6 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Average Weight Loss On Zepbound

This update makes Average Weight Loss On Zepbound more specific by tying semaglutide, tirzepatide, retatrutide, cash-pay pricing, safety signals, average to the page's original clinical, cost, access, or comparison angle.

The goal is to make the article more useful for people who already know the headline question and need page-level specifics, not another interchangeable glp-1 weight loss summary.

For 2026 review, the content emphasizes current verification, treatment fit, and patient-safety questions that can be discussed with a qualified provider.

Average Weight Loss On Zepbound custom 2026 image for glp-1 weight loss on FormBlends

Custom 2026 image for Average Weight Loss On Zepbound, glp-1 weight loss, and better treatment decision-making.

Image description: Unique image for this page covering Average Weight Loss On Zepbound, glp-1 weight loss, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.